La cadena de opciones muestra datos clave de las opciones de acciones de Satellogic a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Satellogic..

Satellogic (NASDAQ:SATL) Bolsa, Cadena de Opciones

Satellogic

Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.

Quantum,Computing,Concept,,Quantum,Mechanics,,Advanced,Technology,,Artificial,Intelligence,And

AMAT

BFRI

CISO

CLIK

DOCS

GLOB

HCTI

IXHL

KLRS

LGPS

ORGN

PTIX

QUBT

SATL

SPCE

TSSI

TVTX

Descubre las acciones que destacan en el premercado de EE. UU.: Quantum Computing sube tras superar expectativas, mientras otras caen.

Acciones de Quantum Computing (QUBT) se disparan un 12%; aquí están 20 acciones que se mueven en premercado

Satellogic Inc

Zozo Inc

Canaccord Genuity analyst Brian McNamara maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and maintains $25 price target.

News

Price Target

Analyst Ratings

EZPW

Canaccord Genuity Maintains Buy on EZCORP, Maintains $25 Price Target

Just two days after Fed Chair Jerome Powell refused to pre-commit to a September rate cut, the U.S. labor market <a href="https://www.benzinga.com/markets/economic-data/25/08/46792479/july-nonfarm-payrolls-trump-powell-labor-market">did it for him. </a>
<ul class="wp-block-list">
<li>SPY ETF breaks past support. <a href="https://www.benzinga.com/quote/SPY">See real-time price here.</a> </li>
</ul>
A weak July jobs report and the biggest downward 2-month revisions since 2020 have economists—and markets—racing to President Donald Trump's side on calling for lower interest rates. 
<h3 class="wp-block-heading">Labor Data Breaks Down And Manufacturing Is Not Helping Either</h3>
The U.S. economy added just 73,000 jobs in July, far below the 110,000 expected. 
But the real shock came from the Bureau of Labor Statistics revising May and June non-farm payrolls down by a combined 258,000—erasing what were thought to be solid job gains. This is the largest two-month revision since the COVID-19 shock in 2020.
Private-sector job growth was narrowly concentrated, driven largely by healthcare, while government payrolls fell by 10,000. The unemployment rate edged up to 4.2%, reversing June's drop.
Wages, however, remained hot. Average hourly earnings rose 0.3% month-over-month and 3.9% year-over-year, both beating forecasts. 
Still, signs of underlying weakness in the labor force—especially due to declining immigration—are mounting.
Meanwhile, U.S. manufacturing continues to struggle, signaling ongoing headwinds from tariff-driven uncertainty. 
The ISM Manufacturing PMI decreased to 48 in July 2025, down from 49 in June and below the expected level of 49.5. It marked the fifth straight month of contraction and the lowest reading since October 2024.
<h3 class="wp-block-heading">Wall Street Moves To The Dovish Side</h3>
Markets are now fully pricing in two rate cuts by December, with the chance of a September 25-basis-point cut surging to 76% Friday, more than double Thursday's odds.
Oxford Economics' Nancy Vanden Houten said the weak July report and historic revisions "raise the odds of a Fed rate cut in September." She warned that slower labor force growth, especially among foreign-born workers, may mask deeper structural issues.
"The foreign-born labor force has shrunk by 1.2 million in just six months," she said, linking the decline to the Trump administration's immigration policies.
"Powell's take on September not being a live meeting might be under revision as we speak," said BOK Financial's analyst Steve Wyett, citing the sharp downward revisions.
David Russell, analyst at TradeStation, indicated that "huge negative revisions undermine beliefs about the strength of the labor market," but warned that "there are still signs of stagflation, with hourly earnings up more than expected."
Jamie Cox, managing partner for Harris Financial Group, weighed in. "Powell is going to regret holding rates steady this week. September is a lock for a rate cut—and it might even be 50 basis points." 
Bill Adams, chief economist at Comerica Bank, struck a more cautious tone. He said the weak July jobs report adds pressure on the Fed to cut rates later this year, but warned the decision "isn't a slam dunk." Adams said the Fed will closely watch the August jobs report and inflation data before making its next move. 
Yields on two-year Treasury bonds, which are highly sensitive to interest-rate expectations, tumbled 22 basis points to 3.75%, eyeing the largest intraday drop since August 2024.
The U.S. dollar index – as closely tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – fell 1.2% by 10:30 a.m. in New York, trimming weekly gains. 
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46766944/stock-market-outlook-sp500-august-seasonality-magnificent-seven">Stock Market Outlook: July&#8217;s Highs Mask A Dangerous August Twist</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Macro Economic Events

Currency ETFs

Forex

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Economists Flip To Trump's Side After Jobs Data–And Jerome Powell Is Now In Trouble

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and maintains $106 price target.

DXCM

Canaccord Genuity Maintains Buy on DexCom, Maintains $106 Price Target

RBC Capital analyst Brad Heffern maintains AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) with a Sector Perform and lowers the price target from $216 to $211.

RBC Capital Maintains Sector Perform on AvalonBay Communities, Lowers Price Target to $211

Stifel analyst Selman Akyol maintains DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) with a Buy and raises the price target from $102 to $108.

Stifel Maintains Buy on DT Midstream, Raises Price Target to $108

"Shark Tank" investor<a href="https://www.benzinga.com/news/topics/25/07/46347662/kevin-oleary-says-trump-and-elon-have-to-get-back-together-again-praises-trumps-big-beautiful-bill"> Kevin O'Leary</a> has a simple secret for staying motivated: he loves proving people wrong. "I just love it when people tell me, ‘Oh, you can't do this, you can't do that,'" O'Leary recently told <a href="https://fortune.com/2025/07/04/shark-tank-kevin-oleary-haters-motivation-not-about-money-business-steve-jobs-founders-mindset/">Fortune.</a>
&nbsp;"When someone tells me I can't do it, I turn around, two years later, kick their ass," he continued. "That's a great motivation. It's not about the money anymore—I just like kicking their ass." O'Leary shot to fame on "Shark Tank," where his tough negotiating style and his acerbic wit earned him the nickname "Mr. Wonderful."&nbsp;
Whether you love him or hate him, it's impossible to deny that O'Leary is a successful businessman with a keen eye for investing and potential profit opportunities. He made his fortune by starting his own company, SoftKey Software Products, and then selling it for $3.7 billion.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a></li>
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
</ul>
Most people would be happy to ride off into the sunset and enjoy a life of leisure after making that kind of money, but O'Leary is not like most people. He relishes the idea of developing new businesses and moving into different industries. O'Leary told Fortune that his expansion into new fields often precedes a spate of "industry experts" and haters to offer their opinions on why his new venture can't work.
For O'Leary, that's like waving a red flag in front of a bull. His entry into the watch insurance industry is his favorite case of proving his doubters wrong.&nbsp; He said some people went so far as to tell him it would be "impossible" for him to get his business off the ground and that the field was "too niche" to accommodate a new player. Despite that, O'Leary launched his WonderCare watch insurance business in April 2024.
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
Although O'Leary has a wildly successful track record as a businessman, it doesn't mean he hasn't experienced setbacks or made bad investments. He sees it as part of the process. "I'm fairly lucky. I've made lots of mistakes investing," he told Fortune. "But I've also had extraordinary outcomes. I'm not scared to fail. I've never bet the farm on anything."
O'Leary said he views having a "founder's mindset" as a key element of his success as a businessman and entrepreneur. He says he developed this mindset while working with Apple (NASDAQ:<a href="https://www.benzinga.com/quote/AAPL"> AAPL</a>) co-founder<a href="https://www.benzinga.com/personal-finance/management/25/07/46383879/steve-jobs-was-adopted-and-unknowingly-dined-at-his-birth-fathers-restaurant-his-dad-remembered-him-only-as-a-great-tipper"> Steve Jobs</a> in the late 1990s. O'Leary noticed that Jobs was always laser-focused on his own vision and had a unique ability to block out external &#8220;noise." He also concedes that it took time and effort to develop that trait in himself.&nbsp;
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
"I've had to work on it, because I didn't even know that was important till I went through my whole thing with Jobs way back in the early 90s," O'Leary said. "But I also deal with it in every aspect of what I'm doing…[If] business is biting, you focus on making money or losing money." O'Leary's sustained success in business would seem to suggest that he has mastered this mindset.
That's not to say that O'Leary doesn't take time to stop and smell the roses. He has pursuits outside of making money that help keep him centered. "I also have interest in photography, in watch collecting, guitar collecting, guitar playing, all kinds of things that I focus on to balance where my head is at," he told Fortune. "To keep the creative yin and yang."
Read Next: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
Image: Imagn Images

'Shark Tank' Star Kevin O'Leary's Main Motivation Is Proving His Haters Wrong, Not Making Money

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 17.96%. Currently, Kinsale Cap Gr has a market capitalization of $10.30 billion. 
Buying $100 In KNSL: If an investor had bought $100 of KNSL stock 5 years ago, it would be worth $226.94 today based on a price of $442.00 for KNSL at the time of writing.
<h3>Kinsale Cap Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754061327_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

KNSL

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Stifel analyst Peter McGoldrick maintains Columbia Sportswear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) with a Buy and lowers the price target from $75 to $68.

COLM

Stifel Maintains Buy on Columbia Sportswear, Lowers Price Target to $68

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and lowers the price target from $142 to $137.

CORT

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Lowers Price Target to $137

WIIM

MPWR

Monolithic Power Systems shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 sales guidance above estimates.

The Trump administration is preparing a pilot program that could allow some Americans on Medicare and Medicaid to access popular and costly <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">weight-loss medications</a>.
The plan, still in development, would permit state Medicaid programs and Medicare Part D plans to voluntarily cover GLP-1 drugs such as Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy, and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound for weight management, according to internal documents reviewed by The Washington Post.
The pilot would also include Eli Lilly&#8217;s GLP-1 drug Orforglipron, pending its expected approval in 2026.
The initiative, set to launch in April 2026 for Medicaid and January 2027 for Medicare, would run through the Center for Medicare and Medicaid Innovation (CMMI).
This testing lab explores new payment models to improve care and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce health care spending</a>.
While Medicare covers these drugs mainly for Type 2 diabetes, some private insurers already approve them for weight loss.
The proposal comes after the Trump administration rejected a Biden-era plan to provide coverage of GLP-1 drugs for weight loss under Medicare and Medicaid.
Though not yet finalized, the Washington Post <a target="_blank" href="https://www.washingtonpost.com/health/2025/08/01/medicare-medicaid-weight-loss-drugs/" rel="noreferrer noopener">report</a> on Friday added that the new pilot could move forward without requiring a formal public comment process.
Also Read: <a href="https://www.benzinga.com/news/fda/25/07/46641326/congress-sounds-alarm-over-illegal-weight-loss-drug-imports-from-china" target="_blank" rel="noreferrer noopener">Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China</a>
Covering these drugs is not without significant cost concerns. The Congressional Budget Office estimates Medicare could spend around $35 billion on GLP-1 coverage for obesity between 2026 and 2034. These medications typically cost $5,000 to $7,000 annually per patient.
Still, experts like David Rind, chief medical officer at the Institute for Clinical and Economic Review, argue the price is reasonable given the potential for substantial health improvements.
Some states are already moving ahead. Thirteen state Medicaid programs currently cover GLP-1s for obesity, despite looming worries about reduced federal Medicaid funding due to a recent tax law overhaul.
On Thursday, Trump issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or <a href="https://www.benzinga.com/news/health-care/25/08/46783827/trump-issues-60-day-ultimatum-to-us-pharma-giants-to-slash-drug-prices-if-you-refuse-to-step-up-" target="_blank" rel="noreferrer noopener">face severe consequences</a>.
Trump urged drugmakers to offer all existing drugs to Medicaid patients at the lowest prices in other developed countries, adopt most-favored-nation pricing for all new drugs across Medicare, Medicaid and commercial payers, and push back against &#8220;foreign freeloading nations&#8221; in pricing negotiations.
Also, Ozempic may enter the realm of price negotiations between&nbsp;<a target="_blank" href="https://www.benzinga.com/news/23/09/34167088/novo-nordisks-famed-drug-ozempic-could-be-a-contender-for-medicare-negotiations" rel="noreferrer noopener">drug manufacturers and Medicare</a>.&nbsp;
Ozempic is poised to become eligible for negotiations when the next batch of drugs is chosen in 2025, leading to price adjustments in 2027.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/08/46793390/putin-disregards-trumps-sanctions-deadline-touts-war-gains-on-ukraine-disappointments-arise-from-inflated-expectations" target="_blank" rel="noreferrer noopener">Putin Disregards Trump&#8217;s Sanctions Deadline, Touts War Gains On Ukraine: &#8216;Disappointments Arise From Inflated Expectations&#8217;</a></li>
</ul>
Photo by KK Stock via Shutterstock

Biotech

Government

Large Cap

Health Care

General

Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) with a Outperform and raises the price target from $8 to $9.

AUPH

RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $9

During Conference Call, Imperial Oil Reportedly Says First Production Of Renewable Diesel From Strathcona Facility In Alberta Took Place In July

Stifel analyst Adam Borg maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Buy and raises the price target from $175 to $230.

Stifel Maintains Buy on Cloudflare, Raises Price Target to $230

AptarGroup shares are trading lower after the company reported Q2 financial results and issued Q3 adjusted EPS guidance below estimates.

Stifel analyst Stephen Gengaro maintains Cactus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) with a Buy and lowers the price target from $57 to $53.

Stifel Maintains Buy on Cactus, Lowers Price Target to $53

LPLA

LPL Financial Holdings shares are trading lower. The company reported Q2 financial results.

RBC Capital analyst Lisa Walter maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and raises the price target from $17 to $19.

APLS

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Raises Price Target to $19

PCOR

Procore Technologies shares are trading lower after the company reported Q2 financial results. Also JMP Securities downgraded the stock from Market Outperform to Market Perform.

Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy and maintains $15 price target.

CMPS

Canaccord Genuity Maintains Buy on Compass Pathways, Maintains $15 Price Target

Press Releases

Satellogic and Telespazio Brasil Announce Multi-Year Contract for Low-Latency Satellite Imagery for the Brazilian Air Force

Earnings

Satellogic Reports 2024 Financial Results and Business Update

Satellogic Finalizes Move to U.S. Jurisdiction to Strengthen Market Position and Investor Access

Contracts

Satellogic Awarded $30 Million Contract for Its AI-First Constellation Services

Satellogic Announces Closing of $20 Million Registered Direct Offering of Class A Common Stock

Satellogic Secures Multi-Million Dollar Agreement with Asia Pacific Customer

Satellogic Reports First Quarter 2025 Financial Results and Provides Business Update

Satellogic Poised to Deliver Its NextGen Satellite and Technology Transfer for Malaysia's Earth Observation Satellite Program

Comments

Satellogic

Satellogic (SATL) Opciones

Satellogic (NASDAQ:SATL) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL